AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03871452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ankaferd Blood Stopper in theTraumatic Bleeding
Description: ankaferd blood stpper They were trained to apply compression of approximately 3-kg weight after irrigation with saline in patients with active bleeding who met inclusion criteria. Bleeding was controlled in every minute and data were collected. Traditional methods such as primary suturing were performed in patients whose bleeding did not stop within 10 minutes. Patients whose bleeding was stopped were monitored for half an hour for bleeding recurrence.~The patients were divided into two groups; ones treated by ABS soaked wet compresses (group I) and ones treated by dry sponge compresses
Study NCT03425721 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention is administered in this study.
Study NCT01300819 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patches of 2, 4, 6 \& 8 mg / 24 hours Daily application of Placebo patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose was 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day.
Study NCT02227589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D-TAU
Description: D-TAU is treatment as usual in the community, targeting depression. It may consist of medication and/or behavioral intervention.
Study NCT02248610 — intervention group
Intervention type: OTHER
Intervention: Non-interventional study
Study NCT03108027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
Description: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
Study NCT03108027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
Description: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
Study NCT02914860 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: D-SPECT
Study NCT02914860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D-SPECT
Study NCT02600533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video viewing group
Description: First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
Study NCT01269541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin
Description: Topical in the nose 3 times daily for 5 days
Study NCT01269541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin+Clindamycine or Trimehoprimsulfa
Description: Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
Study NCT01300819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine patches of 2, 4, 6, and 8 mg / 24 hours~Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day.
Study NCT04347980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone and Hydroxychloroquine
Description: Patients included in the Hydroxychloroquine / Dexamethasone group will benefit from standardized ventilatory management and administration of Hydroxychloroquine in the same manner as the Hydroxychloroquine group. They will receive in addition to Dexamethasone at a rate of 20 mg intravenously for 15 min once a day for 5 days (D1 to D5) then at a rate of 10 mg per day from D6 to D10. If the patient is extubated before the 10th day, he will receive his last dose of Dexamethasone before.
Study NCT04347980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Patients included in the Hydroxychloroquine group will benefit from standardized ventilatory management. Patients included in the Hydroxychloroquine group will receive 200 mg x 3 / day enterally from J1 of the HCQ for 10 days. If the patient is extubated before the 10th day, he will receive his last dose of HCQ before.
Study NCT01476280 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: palonosetron
Description: 0.075mg immediately before induction of anesthesia
Study NCT01476280 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ramosetron
Description: 0.3mg immediately before induction of anesthesia
Study NCT05215015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD33/CLL1 CAR-NK Cells
Description: The administration of CAR-NK cells will be performed on day 1 and day 3 of each cycle (28 days). The first administration dose in the first cycle is 2.0×10\^9 cells. If no adverse events were observed, the second administration dose in the first cycle would be 3.0×10\^9 cells, and each administration dose in the second cycle and thereafter would be 3.0×10\^9 cells.
Study NCT03777917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero Balance®
Description: Belotero® Balance for infraorbital hollows. Mode of application: subdermal injection.
Study NCT02585648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo Gel and Thealoz Duo eye drops
Description: Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)
Study NCT02585648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo eye drops
Description: Thealoz Duo eye drops during the day (4 to 6 drops per day)
Study NCT02087813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha1-antitrypsin
Study NCT02087813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.
Study NCT02087813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: 3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.
Study NCT02211196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation intervention
Description: Receive evidence-based tobacco cessation strategies
Study NCT02211196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies
Study NCT02242175 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Glucose breath test (hydrogen breath test)
Description: Glucose breath test (hydrogen breath test) is the current gold standard for diagnosis of irritable bowel syndrome. Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen or methane gas as a by-product. The breath sample will be analyzed for hydrogen or methane content to determine if you are able to properly break down the lactose, fructose or sucrose, or if you have bacterial overgrowth.
Study NCT01287221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: 300 mg, 2 times daily
Study NCT01955499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01955499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01955499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT01138384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foretinib
Description: Daily oral dosing at assigned dose beginning day 3 of cycle 1
Study NCT01138384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Daily oral dosing at assigned dose beginning day 1 cycle 1.
Study NCT00000170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine
Study NCT00000170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Patch
Description: Patching
Study NCT02611869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon
Description: Pulmonary vein isolation by cryoablation using a 2nd generation cryoballoon catheter
Study NCT02611869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RF ablation
Description: Pulmonary vein isolation by radiofrequency current ablation using a touch-force-sensing irrigated catheter
Study NCT04486703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with music
Description: physical therapy program combined with music therapy 15 min, 3 times weekly for 12 weeks.
Study NCT00911638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient decision aid
Description: Patients will receive i) Patient education:usual take home education brochure from recruiting hospital ii)a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form:an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referred onward to the surgeon with their preferences for surgery using a standardized report of their clinical findings plus decisional data (knowledge, values, preference).
Study NCT00911638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients will receive i) the usual take-home educational brochure available at the recruiting hospital describing preparation for surgery after the decision is made, recovery after surgery, and discharge plans.~ii) Referral onward to surgeon with a standardized report of clinical findings only
Study NCT00911638 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will receive i) the usual take-home educational brochure available at the recruiting hospital describing preparation for surgery after the decision is made, recovery after surgery, and discharge plans.~ii) Referral onward to surgeon with a standardized report of clinical findings only
Study NCT03942094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib (Tasigna ®), capsules of 150 mg~Nilotinib 2 capsules of 150 mg, orally, twice daily
Study NCT04012970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual spinal mobilisations
Study NCT01960738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A pre-dive checklist
Description: The pre-dive checklist included a checklist of tasks to be undertaken before the dive, a dive-plan that asked the diver to plan the depth, and amount of gas kept at different levels of diving, and 4 dive tips.
Study NCT01287221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03340415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated Rehabilitation plan
Description: early weight bearing after surgery
Study NCT03615833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol 2.5mg (100 000 UI) , once a month for 3 months
Study NCT00110669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone and dummy preparations for this study will be obtained from Frank's Pharmacy in Ocala, FL and will be supplied as a tablet containing 2.5mg, 5mg, 10mg, 20mg or 50mg Prednisone. Inactive dummy pills of similar look/taste will be supplied to maintain blinding.
Study NCT04872296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Ankle Motion (CAM) boot
Description: A CAM boot will be worn on the affected ankle to allow weight bearing
Study NCT04872296 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Standard physical therapy protocol will be started at 6 weeks after surgery
Study NCT02489656 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double Loop Ureteral stent endoscopic placement.
Description: A JJ stent placement may be indicated at the end of the endourological removal of kidney stones to ensure urine drainage and cicatrisation
Study NCT02489656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double Loop Ureteral stent endoscopic placement.
Description: A JJ stent placement may be indicated at the end of the endourological removal of kidney stones to ensure urine drainage and cicatrisation
Study NCT03737344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IL-1Ra Kineret®
Description: Kineret® 100 mg in 0.67 ml Prefilled Syringe
Study NCT03737344 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IL-1Ra Placebo
Description: Placebo identical to Kineret® 100 mg in 0.67 ml Prefilled Syringe
Study NCT02324049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBC-103
Study NCT02618512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBC-103
Description: SBC-103 is a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU). Patients were started with low dose of SBC-103 for 12 weeks and then will escalate to a higher dose.
Study NCT04698954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Improving self-Management Strategy
Description: The AIMS intervention is a conversation between a patient and a trained nurse, imbedded in the usual care. It consists of structured modules with visual materials, developed based on a sound understanding of the factors that drive non-adherence and potent behaviour change techniques to modify those. These modules aim to enhance patient knowledge, motivation, self-efficacy, and skills for self-managing their treatment. As part of the intervention, patients use electronic monitors to track their own behaviour, namely a medication and a physical activity monitor. Together with the nurse they examine these results to identify adherence problems and solutions and make a plan.
Study NCT04698954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Participants in the control group will receive treatment as usual. They will visit the nurse in the out patient clinic each 3 or 6 months for 30 minutes.
Study NCT03170765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles vaccine
Description: Live attenuated measles vaccine of brands currently being used in National Immunization Schedule of India.
Study NCT03170765 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles vaccine
Description: Live attenuated measles vaccine of brands currently being used in National Immunization Schedule of India.
Study NCT02625363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Ref - Std
Description: First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
Study NCT02625363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose Ref and 450 ml water
Description: First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes. Subjects given additional 150 ml water at 45, 75, and 105 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120
Study NCT02625363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Bread with 250 ml water
Description: First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
Study NCT02625363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Bread and 700 ml water
Description: Sample consumed with 250 ml water immediately after meal consumption, and additional 150 ml water at 45, 75, and 105 minutes.~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
Study NCT04952038 — intervention group
Intervention type: BEHAVIORAL
Intervention: sleep disorder
Description: ALS patients with or without sleep disorder
Study NCT01485380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: The dexmedetomidine infusion will be individualized to each study participant by a target plasma concentration where loss of consciousness is initially observed. Loss of consciousness will be assayed by specific auditory and verbal stimuli.
Study NCT01945775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talazoparib
Description: Until progression or unacceptable toxicity develops
Study NCT01945775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's-Choice
Description: Capecitabine, Eribulin, Gemcitabine or Vinorelbine
Study NCT05315375 — intervention group
Intervention type: DEVICE
Intervention: corpectomy
Description: vertebral corpectomy using expandable cage
Study NCT02649192 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza virus vaccine
Description: Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.
Study NCT02649192 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza virus vaccine
Description: Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.
Study NCT02649192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamins A and D
Description: The chewable gummy contains either Vitamin A (20,000 International Units) and Vitamin D3 (2,000 International Units), which should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
Study NCT02649192 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The chewable gummy matched placebo will be formulated with gelatin base and tangerine oil and match the Vitamin A and D in shape, taste, texture, and appearance. Gummies should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
Study NCT03164083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell
Description: intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation
Study NCT03164083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients with knee joint osteoarthritis who underwent intra articular placebo injection
Study NCT01281098 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation (PRP)
Description: Panretinal Photocoagulation (PRP)
Study NCT01281098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal Photocoagulation (PRP)
Description: Panretinal Photocoagulation (PRP)
Study NCT01281098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreous injection of pegaptanib
Description: Intravitreous injection of pegaptanib
Study NCT00892606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Patients will receive 0.2 mg/kg of methadone IV immediately after intubation
Study NCT00892606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Patients will receive 0.2 mg/kg of morphine IV immediately after intubation
Study NCT02322294 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucodia™
Study NCT02322294 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01787318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePID closed loop system
Description: Insulin pump controlled by closed loop unit and algorithm
Study NCT01787318 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ePID closed loop system
Description: Insulin pump controlled by closed loop unit and algorithm
Study NCT01787318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InsuPatch
Description: device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site
Study NCT03833570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rapid Release Capsules Melatonin, 10 mg
Description: Melatonin is a dietary supplement which is naturally produced in the body and closely involved in the natural sleep cycle. recently topical and systemic melatonin supplements. have been proposed as a new therapeutic modality for oral mucositis due to its anti-cancer, anti-inflammatory, and anti-oxidant effects.
Study NCT03833570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miconaz oral gel
Description: Antifungal agent